John F de Groot, MD, neuro-oncologist, The University of Texas MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.
In a trial, mice were treated with altiratinib alone, bevacizumab alone, or a combination of the two agents. De Groot says the combination dramatically reduced tumor volume and tumor invasion.
De Groot speculates that the combination worked so well because it was able to block myeloid cell infiltration and reduce angiogenesis in order to decrease tumor cell invasion.
<<< View more from the 2014 Society for Neuro-Oncology Annual Meeting